Red Light Holland gets its VR "experience" hosted on the largest PC gaming platform.
MINDCURE (CSE: MCUR) (OTCQB: MCURF) Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform
MindMed Announces C$19.5 Million Bought Deal Private Placement Offering
MindMed raises CAD$19.5 million selling units at CAD$3.25.
Other Psychedelic Stocks Get Cheaper As atai Gets More Expensive
If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.
MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
ATAI announces closing its Series D financing round, raising $157 million.
MINDCURE (CSE: MCUR | OTCQB: MCURF) Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
The Company expects to have ibogaine manufactured and in use for research by Q4.
MINDCURE Completes Its Initial Strategic Equity Investment in ATMA, Canada's First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
MINDCURE makes a CAD$500,000 strategic investment in ATMA Journey Centers, an Alberta-based psychedelics-assisted mental health clinic.
MINDCURE (CSE: MCUR | OTCQB MCURF) Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
The completed equity investment strengthens ties between MINDCURE and ATMA
Biggest Opportunities for Psychedelic Drugs OUTSIDE of Mental Health?
The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Mydecine exports dried psilocybin mushrooms from Jamaica to Canada.
